Table 1.
Summarized Immune monitoring results of Vaccine B.
| Peptide No. | AA sequence | Gene | HLA | CD4 | CD8 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | VQSEPCNGMV | APC : NM_000038.6:c.4232G>A:p.S1411N | A*02:06 | 0,9 | 29,8 | 11,7 | 8,9 | 0,7 | 2,5 | 1,2 | 1 |
| 17 | FVRGLQREL | CGN : NM_020770.3:c.1657C>T:p.L553F | C*12:03 | 1,1 | 1,1 | ||||||
| 18 | TSPSYSPTY | POLR2A:NM_000937.5:c.5045C>A:p.S1682Y | C*12:03 | ||||||||
| 20 | RVDHVMGSV | NEIL3:NM_018248.3:c.932A>G:p.D311G | A*02:06, C*12:03 | ||||||||
| 21 | ALILTPTRV | DDX59:NM_001031725.6:c.845_846delAG:p.E282Vfs*10 | A*02:06 | 1,1 | 0,9 | ||||||
| 23 | TTPTGTQAAYTRPTVSP | EMSY : NM_020193.4:c.1525A>G:p.T509A | Class II | 1,2 | 22,8 | 3,3 | 32,3 | 1,0 | 0,9 | 1,0 | 1,5 |
| 25 | LQQIFESQHMKFSEIPQ | SMARCD1:NM_003076.5:c.1052G>A:p.R351H | Class II | 16,8 | 2,4 | 1,0 | 3,6 | ||||
| 26 | PPPKVVDVSSHASQSAR | ATN1:NM_001940.4:c.2269C>T:p.P757S | Class II | 1,0 | 129,1 | 22,2 | 10,3 | 0,8 | 0,9 | 1,5 | 1,9 |
| 30 | ALILTPTRVSHSDRETS | DDX59:NM_001031725.6:c.845_846delAG:p.E282Vfs*10 | Class II | 101,0 | 2,7 | ||||||
| 31 | KVHEEIERAIGANRAPS | CYP2U1:NM_183075.3:c.1154T>C:p.V385A | Class II | 62,3 | 1,9 | ||||||
| 14 | TRFRAMAIY | TP53:NM_000546.6:c.469G>T:p.V157F | C*12:03 | 1,0 | 1,1 | 1,0 | 1,0 | 0,8 | 1,2 | 2,4 | 0,8 |
| 15 | TQAAYTRPTV | EMSY : NM_020193.4:c.1525A>G:p.T509A | A*02:06 | 1,1 | 1,4 | 1,0 | 0,7 | 29,2 | 1,1 | ||
| 16 | TTWNILPSV | MT-CO1:ENST00000361624:m.7264T>C:p.S454P | A*02:06, C*12:03 | 0,8 | 1,3 | ||||||
| 19 | VHEEIERAI | CYP2U1:NM_183075.3:c.1154T>C:p.V385A | B*38:01 | 1,0 | 1,1 | ||||||
| 22 | STPPPGTRFRAMAIYKQ | TP53:NM_000546.6:c.469G>T:p.V157F | Class II | 1,6 | 1,6 | 16,0 | 7,2 | 0,8 | 1,6 | 0,8 | 1,9 |
| 24 | SSVQSEPCNGMVSGIIS | APC : NM_000038.6:c.4232G>A:p.S1411N | Class II | 1,2 | 85,4 | 31,1 | 1,0 | 0,9 | 1,1 | ||
| 32 | SKGLLPNNLEESGICHK | XPR1:NM_004736.4:c.1301C>T:p.S434L | Class II | 6,1 | 1,2 | ||||||
| 33 | EEAEESTPTQKRKGRQS | TSHZ3:NM_020856.4:c.2662G>A:p.A888T | Class II | 3,6 | 27,4 | 1,0 | 0,7 | 1,4 | 1,1 | ||
| 34 | SSRVDHVMGSVARKSEE | NEIL3:NM_018248.3:c.932A>G:p.D311G | Class II | 12,9 | 31,5 | 1,2 | 2,0 | ||||
| 36 | PGPSDPGPDVNRTESPM | PRRT3:NM_207351.5:c.1130C>A:p.A377D | Class II | 1,3 | 0,5 | ||||||
| M0 | M3 | M8 | M13 | M0 | M3 | M8 | M13 | ||||
AA, amino acid; HLA, Predicted HLA I restriction. Numbers indicate the Stimulation Index (SI): ratio of polyfunctional activated CD4+ or CD8+ T-cells (positive for at least two activation markers of CD154, IFN-γ, TNF-α and/or IL-2) in the peptide-stimulated sample compared to the unstimulated control. Blue boxes indicate presence of neoantigen-specific T-cells. Neoantigen-specific T-cells are defined as being present for SI >2. Due to low cell numbers, some peptides were analysed in pools (e.g. peptide no. 1, 17, 18, 20, 21). Mx: months after first vaccination of Vaccine B. *: this peptide was included in Vaccine A as well.